stockrow
Saturday 7 November 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024.
- Revenue
- −5.30%
- EPS
- +102.0%
- Free cash flow
- −10.9%
- Total debt
- −1.51%
Quarter to June 2026, against a year earlier
0.76
0.03
+4.11%
Follow CELU
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.34 | 1.07 | 2.04 | 0.94 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(13.11) | (5.57) | 26.72 | (15.81) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.33 | 2.64 | 4.19 | 3.20 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(14.39) | (5.29) | (9.01) | (6.69) | |
EV/FCF |
(14.05) | (5.22) | (8.85) | (6.57) | |
Quick Ratio |
0.10 | 0.13 | 0.07 | 0.09 | |
Current Ratio |
0.16 | 0.15 | 0.09 | 0.11 | |
Net Debt/EBITDA |
(3.58) | (2.06) | (4.77) | (15.64) | |
Debt/Assets |
34.98% | 44.55% | 41.32% | 44.48% | |
Debt/Equity |
(1.99) | (1.26) | (1.17) | (1.20) | |
Asset Turnover |
0.33 | 0.22 | 0.17 | 0.17 | |
Operating CF/Net income |
0.18 | 0.21 | 2.14 | (2.03) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(8.73) | (24.59) | (28.79) | (23.94) | |
Research and Development Expense of Revenue |
87.02% | 81.55% | 77.85% | 37.33% | |
Selling, General and Administrative Expense of Revenue |
176.12% | 367.06% | 238.30% | 90.94% | |
Intangible Assets out of Total Assets |
0.14 | 0.14 | 0.15 | 0.14 | |
Share Based Compensation of Revenue |
38.63% | 79.24% | 32.32% | 15.54% | |
Graham Net Nets |
(2.27) | (4.68) | (3.32) | (7.15) | |
Graham Number |
7.56 | 10.96 | 8.63 | 6.80 | |
Earnings Yield |
(160.87%) | (323.42%) | (205.26%) | (281.67%) | |
Free Cash Flow Yield |
(12.32%) | (47.21%) | (23.21%) | (51.84%) | |
Revenue per Share |
0.20 | 0.16 | 0.13 | 0.19 | |
Operating CF per Share |
(0.16) | (0.20) | 0.05 | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.20) | 0.05 | (0.04) | |
Cash per Share |
0.00 | 0.24 | 0.01 | 0.02 | |
Shareholders Equity per Share |
(0.76) | (1.49) | (1.21) | (1.22) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.76) | (1.49) | (1.21) | (1.22) | |
Free Cash Flow |
(4.16) | (5.10) | 1.45 | (1.11) | |
Working Capital |
(54.72) | (68.44) | (64.28) | (53.29) | |
Net Current Asset Value |
(123.74) | (133.07) | (128.44) | (125.25) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.74 | 9.11 | 9.87 | 7.92 | |
Average Payables |
19.99 | 24.86 | 24.21 | 19.49 | |
Average Inventory |
3.26 | 2.99 | 3.34 | 2.56 | |
Average Assets |
121.54 | 120.01 | 114.18 | 108.23 | |
Average Common Equity |
(1.41) | (14.61) | (20.38) | (30.51) |
Columns are period end dates · fundamentals updated 2 Nov 2026